Drug intelligence / Profile preview

BMS-926796

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules

Overview

BMS-926796 is a metabolite of the investigational drug BMS-911543, which was developed as a small molecule inhibitor primarily for use in cancer indications such as myelofibrosis. BMS-926796 is measured in pharmacokinetic studies as "Met4" to assess the metabolism and distribution of BMS-911543 in patients. Specific direct pharmacologic properties, indications, or mechanisms of BMS-926796 as an independent agent are not reported; it functions as a metabolite rather than a primary therapeutic compound[1].

Other names: Met4Met-4Met 4

Beyond the preview

Go deeper on BMS-926796.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-926796.

Explore the full profile